ORIGINAL PAPER
Interactions of infection history with vaccine immune responses in pediatric patients with Kawasaki disease
 
 
More details
Hide details
1
Shunyi Maternal and Children’s Hospital of Beijing Children’s Hospital, Beijing 101300, China
 
 
Submission date: 2025-10-13
 
 
Final revision date: 2025-11-20
 
 
Acceptance date: 2025-11-22
 
 
Online publication date: 2026-09-15
 
 
Corresponding author
Weifang Liu   

Shunyi Maternal and Children’s Hospital of Beijing Children’s Hospital, Beijing 101300, China
 
 
 
KEYWORDS
ABSTRACT
Introduction:
We aimed to assess the influence of infection history in pediatric patients with Kawasaki disease (KD) on vaccine immune responses in the convalescence stage.

Material and Methods:
In this study, a total of 298 pediatric patients who were diagnosed with KD between January 2021 and December 2024 and completed follow-up were included. They were assigned to a high infection burden group (n = 152) and a low infection burden group (n = 146). All pediatric patients underwent immunization with measles-mumps-rubella (MMR), hepatitis B, or varicella vaccine at least 11 months after treatment with intravenous immunoglobulin, and completed serological tests within 1-3 months after vaccination. Antibody levels were measured via enzyme-linked immunosorbent assay, and the positive conversion rates and geometric mean titers (GMTs) were calculated.

Results:
Compared with the low infection burden group, the high infection burden group had a significantly lower positive conversion rate (82.2% vs. 93.2%, p = 0.006) and GMT (320 IU/ml vs. 540 IU/ml, p = 0.010) of measles antibody. High infection burden was independently associated with a higher likelihood of immunization failure in multivariate logistic regression analysis (odds ratio [OR] = 2.35, 95% confidence interval [CI]: 1.20-4.62, p = 0.013). Quartile-stratified analysis indicated that the measles antibody level declined significantly with increasing infection frequency (p for trend = 0.003).

Conclusions:
A history of high infection burden was associated with lower vaccine-induced immune responses. In particular, frequent respiratory tract infection can significantly weaken the vaccine-induced immune responses in the convalescence stage.
REFERENCES (28)
1.
Jone PN, Tremoulet A, Choueiter N, et al. (2024): Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation 150: e481-500.
 
2.
Hu J, Ren W (2021): Analysis of the risk factors in prognosis of Kawasaki disease with coronary artery lesions. Front Pediatr 9: 798148.
 
3.
Ae R, Shibata Y, Kosami K, et al. (2021): Kawasaki disease and pediatric infectious diseases during the coronavirus disease 2019 pandemic. J Pediatr 239: 50-58.
 
4.
Mofors J, Rudolph A, Schiller B, et al. (2025): Associations of infection burden with Kawasaki disease in a population-based setting during 30 years. RMD Open 11: e005160.
 
5.
Liu Y, Huang H, Li X, et al. (2025): Kawasaki disease: insights into the roles of T cells. Front Immunol 16: 1582638.
 
6.
Chu HW, Lin CH, Lin MC, et al. (2021): Increased risk of Kawasaki disease in infants born of mothers with immune disorders. Front Pediatr 9: 659598.
 
7.
Morikawa Y, Sakakibara H, Kimiya T, et al. (2021): Live attenuated vaccine efficacy six months after intravenous immunoglobulin therapy for Kawasaki disease. Vaccine 39: 5680-5687.
 
8.
Cardenas-Brown C, Lucas RD, Buttery J, et al. (2023): Live vaccines following intravenous immunoglobulin for Kawasaki disease: Are we vaccinating appropriately? J Paediatr Child Health 59: 1217-1222.
 
9.
Wang W, Zhu L, Li X, et al. (2023): Emerging evidence of microbial infection in causing systematic immune vasculitis in Kawasaki disease. Front Microbiol 14: 1313838.
 
10.
Liao JW, Guo X, Li XX, et al. (2024): Exploring the diagnostic value of CLR and CPR in differentiating Kawasaki disease from other infectious diseases based on clinical predictive modeling. Front Pediatr 12: 1345141.
 
11.
McCrindle BW, Rowley AH, Newburger JW, et al. (2017): Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135: e927-999.
 
12.
Jone PN, Tremoulet A, Choueiter N, et al. (2025): Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association. Circulation 150: e481-e500.
 
13.
Zhao S, Wang Q, Yang J, et al. (2025): Comparative analysis of long-term measles immune response after natural infection and routine vaccination in China. Vaccines 13: 555.
 
14.
Nakphook S, Patumanond J, Shrestha M, et al. (2021): Antibody responses induced by trivalent inactivated influenza vaccine among pregnant and non-pregnant women in Thailand: a matched cohort study. PLoS One 16: e0253028.
 
15.
Ley D, Lazarus S, Forati AM, et al. (2024): High rates of seroprotection to hepatitis B after a hepatitis B challenge dose in previously vaccinated patients with inflammatory bowel disease on immunosuppressive therapy. Dig Dis Sci 69: 3051-3060.
 
16.
Meng QH, Cheng XP, Liu DD, et al. (2021): One single-center cross-sectional investigation on varicella antibody level of all age groups in Chinese people. Hum Vaccin Immunother 17: 358-362.
 
17.
Zhao L, Wu J, Liu X, et al. (2025): Risk factors for predicting medium-giant coronary artery aneurysms in Kawasaki disease. Immunol Res 73: 52.
 
18.
Agrafiotou A, Sapountzi E, Margoni A, et al. (2025): Immunophenotype of Kawasaki disease: insights into pathogenesis and treatment response. Life 15: 1012.
 
19.
Morikawa Y, Sakakibara H, Miura M. (2022): Efficacy of live attenuated vaccines after two doses of intravenous immunoglobulin for Kawasaki disease. World J Pediatr 18: 706-709.
 
20.
Kim S, Ko HY, Oh J, et al. (2025) Risk of Kawasaki disease/multisystem inflammatory syndrome following COVID-19 vaccination in Korean children: A self-controlled case series study. J Korean Med Sci 40: e10.
 
21.
Li Y, Molleston JM, Lovato C, et al. (2024): Sequential early-life viral infections modulate the microbiota and adaptive immune responses to systemic and mucosal vaccination. PLoS Pathog 20: e1012557.
 
22.
Xie Y, Tian X, Zhang X, et al. (2023): Immune interference in effectiveness of influenza and COVID-19 vaccination. Front Immunol 14: 1167214.
 
23.
Sullivan SG, Khvorov A, Carolan L, et al. (2025): Antibody responses against influenza A decline with successive years of annual influenza vaccination. NPJ Vaccines 10: 11.
 
24.
Akehurst IM, James LK (2025): Tissue resident memory B cells mediate protective immunity to respiratory pathogens in the airways. Immunol Lett 277: 107091.
 
25.
Georgakopoulou VE, Pitiriga VC (2025): Immunomodulation in respiratory syncytial virus infection: mechanisms, therapeutic targets, and clinical implications. Microorganisms 13: 1876.
 
26.
Gambadauro A, Galletta F, Li Pomi A, et al. (2024): Immune response to respiratory viral infections. Int J Mol Sci 25: 6178.
 
27.
Oktaria V, Wiratama BS, Riyanto S, et al. (2025): A scoping review: the impact of nutritional status on the efficacy, effectiveness, and immunogenicity of COVID-19 vaccines. Trop Dis Travel Med Vaccines 11: 21.
 
28.
Lee S, Lee J, Cho SH, et al. (2024): Assessing the impact of mRNA vaccination in chronic inflammatory murine model. NPJ Vaccines 9: 34.
 
eISSN:1644-4124
ISSN:1426-3912
Journals System - logo
Scroll to top